Loading…
Loading…
Can you just tell me a little bit about what you're to get from that study
I was wondering, and to ask your view of the portfolio overall in obesity given that folks like today are disclosing combinations with monthly or monthly and then combinations and how you see this ...
I'm curious about your confidence that we will see very competitive tolerability and very strong efficacy and that, that narrative will hold up?
Can you maybe comment about your strategic view about where you'd like to be in a couple of years, if you are so confident on MariTide
Can you tell us a little bit about the profile of that drug and what you're seeing in Phase one to get you excited
your expectations for the PrEP one. And assuming approval on time, how you think about the dynamics in the second half
can you just comment about your recent interactions with the FDA and the perspective of the FDA and HHS with the incoming administration
Just wanted to ask your expectation on the orforglipron launch general view of unit volume scripts vis-a-vis the tirzepatide launch